Neurologic Morbidity in Survivors of Childhood Hodgkin Lymphoma Treated With Radiation
Pediatric Blood & Cancer · 2026-08 · 73 (8)
DOI: 10.1002/1545-5017.70398 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 12.05.2026. Verfasst von Raja B Khan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Department of Pediatrics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Cancer Survivors, Hodgkin Disease, Nervous System Diseases, Radiotherapy. Die Arbeit nennt 22 Literaturangaben. Gefördert von: NCI NIH HHS, American Lebanese Syrian Associated Charities and National Cancer Institute.
Abstract (Originalsprache)
Background
Hodgkin lymphoma is the most common cancer in adolescence and is treated with chemotherapy and/or radiation therapy. Little is known about neurologic symptoms, signs, and morbidity in long‐term survivors of childhood Hodgkin lymphoma that were treated with radiation. The aim of this study was to identify neurologic symptoms, signs, and related morbidity in survivors of childhood Hodgkin lymphoma who received radiation therapy.
Methods
Long‐term survivors (≥5 years from diagnosis, ≤25 years at diagnosis, and ≥18‐years old at study enrollment) and community controls matched for age, sex, and ethnicity were recruited and provided written consent. Participants answered a questionnaire, followed by a face‐to‐face interview and examination by a neurologist. All survivors were treated with chemotherapy and thoracic/neck radiation therapy.
Results
The study questionnaire and face‐to‐face interview were completed by 197 survivors and 191 controls. Male‐to‐female ratio was 94:103 in survivors and 95:96 in controls. Median age at tumor diagnosis was 14.7 years (range: 3.0–22.6) and median time from tumor diagnosis was 20.9 years (range: 10.7–45.6 years). Headaches (43.2% vs. 32.8%), dizziness (38.1% vs. 19.9%), bladder and (15.8% vs. 9.4%) bowel problems (20.3% vs. 12.8%), and sensory neuropathy (22.1% vs. 5.8%) were more prevalent in survivors. Migraine headaches (32.0% vs. 22.9%) were more prevalent in female survivors but did not reach statistical significance. Neurologic morbidity and disability measures showed low associated morbidity.
Conclusion
While survivors of childhood Hodgkin lymphoma treated with radiation experienced more neurologic symptoms when compared to controls, their neurologic morbidity was low. Trial Registration NCT01820117
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neurology, Department of Pediatrics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Psychology and Behavioral Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Radiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Förderung
- NCI NIH HHS
- American Lebanese Syrian Associated Charities and National Cancer Institute
Zitieren
APA
Khan, R. B., Hanzlik, E., Deokumar, S., Xie, L., Hudson, M. M., Krull, K. R., & Sabin, N. D. (2026). Neurologic Morbidity in Survivors of Childhood Hodgkin Lymphoma Treated With Radiation. Pediatric Blood & Cancer, 73(8). https://doi.org/10.1002/1545-5017.70398
Vancouver
Khan RB, Hanzlik E, Deokumar S, Xie L, Hudson MM, Krull KR, et al. Neurologic Morbidity in Survivors of Childhood Hodgkin Lymphoma Treated With Radiation. Pediatric Blood & Cancer. 2026;73(8). doi:10.1002/1545-5017.70398
BibTeX
@article{Khan2026,
author = {Khan, Raja B and Hanzlik, Emily and Deokumar, Srivastava and Xie, Lu and Hudson, Melissa M and Krull, Kevin R and Sabin, Noah D},
title = {Neurologic Morbidity in Survivors of Childhood Hodgkin Lymphoma Treated With Radiation},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {8},
doi = {10.1002/1545-5017.70398}
}
EUVIMED